Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes: To the editor

New England Journal of Medicine

Volumn 374, Issue 11, 2016, Pages 1092-1093

  Fischereder, Michael ^a   Schönermarck, Ulf ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; PLACEBO; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

AUGMENTED NATRIURESIS; CARDIOVASCULAR OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); GLYCEMIC CONTROL; HEART FAILURE; HOSPITALIZATION; HUMAN; KIDNEY TUBULE ABSORPTION; LETTER; MEDICAL LITERATURE; MORBIDITY; MORTALITY; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; MALE;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE;

EID: 84961830177     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1600827     Document Type: Letter

References (3)

1. Ellison DH, Velázquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat: structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 1989; 83: 113-26.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
3. Toto RD, Wanner C, Gerich J, et al. No overall increase in volume depletion events with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM). J Am Soc Nephrol 2013; 24: Suppl. abstract.